Front Oncol: Efficacy and safety of TACE combined with lenvatinib (TACE-L) vs. TACE combined with sorafenib (TACE-S) in the treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world

A total of 116 patients were recruited in this study (TACE-L, 59 cases; TACE-S 57 cases)

Before propensity score matching (PSM), the median OS in the TACE-L and TACE-S groups were 16.

Before PSM, in the subgroup analysis, based on the number of TACE operations (<3 times), the median OS was 14.

After PSM, in the subgroup analysis, the median OS of Vp2 PVTT patients was 22.

Before PSM, the median progression-free survival (PFS) of the TACE-L and TACE-S groups were 8.

Before PSM, comparing TACE-L and TACE-S, CR was 10.

Multivariate analysis of the PSM cohort, TACE surgery <3 times (HR 0.

In the TACE-L group, 38 patients were observed to have adverse reactions

In summary, studies have shown that TACE-L and TACE-S are both safe and well-tolerated treatments for HCC patients with PVTT

Original source:

Yang B, Jie L, Yang T, Chen M, Gao Y, Zhang T, Zhang Y, Wu H and Liao Z (2021) TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study .